Additionally, existing studies further corroborate the pivotal function of endogenous plasma sRAGE within the AGE-RAGE axis as a prospective catalyst of lung injury, indicating that there is potential for reducing plasma sRAGE levels or targeting the AGER/sRAGE axis to have a preventative or therapeutic effect on inflammation-related lung disease (53–55). The gene discussed is AGER; the disease is inflammation.